ATOSSA THERAPEUTICS, INC. financials

ATOS CIK 0001488039

Source: EDGAR filings · Built 2026-06-19T00:29:44Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -29.79M -21.05M -20.95M -20.79M -16.48M -11.58M
EBITDA -37.13M -27.60M -31.35M -27.68M -20.50M -14.56M
Working Capital 37.36M 69.49M 86.98M 112.63M 138.11M 27.10M
Net Debt -110.89M -136.38M -39.54M
Return on Equity (ROE) -88.35% -35.68% -33.06% -22.85% -14.92% -65.62%
Return on Assets (ROA) -73.03% -33.36% -31.27% -21.82% -14.59% -41.62%
Current Ratio 5.53× 14.99× 17.61× 21.23× 45.18× 2.73×
Debt-to-Equity 0.00× 0.00× 0.00×
Effective Tax Rate 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Cash Conversion Ratio 0.86× 0.82× 0.70× 0.77× 0.80× 0.65×
Accruals Ratio -0.11× -0.06× -0.10× -0.05× -0.03× -0.15×
CapEx Coverage -1294.00× -1106.84× -1495.79× -768.89× -1830.22× -1285.56×
Free Cash Flow Per Share $-3.46 $-2.51 $-0.17 $-0.16 $-140.92 $-1023.87

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Research and Development Expense 21.18M 14.12M 17.33M 15.08M 9.21M 6.61M
Operating Expenses 37.14M 27.62M 31.38M 27.69M 20.52M 14.61M
Operating Income (Loss) -37.14M -27.62M -31.38M -27.69M -20.52M -14.61M
Income Tax Expense (Benefit) 0 0 0 0 0 0
Net Income (Loss) Attributable to Parent -34.77M -25.50M -30.09M -26.96M -20.61M -17.83M
Earnings Per Share, Basic $-4.04 $-3.04 $-0.24 $-0.21 $-0.18
Weighted Average Number of Shares Outstanding, Basic 8.61M 8.39M 126.08M 126.62M 116.95M
Earnings Per Share, Diluted $-4.04 $-3.04 $-0.24 $-0.21
Weighted Average Number of Shares Outstanding, Diluted 8.61M 8.39M 126.08M 126.62M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 41.30M 71.08M 88.46M 110.89M 136.38M 39.55M
Assets, Current 45.62M 74.46M 92.22M 118.20M 141.24M 42.77M
Assets 47.61M 76.44M 96.25M 123.53M 141.26M 42.84M
Liabilities, Current 8.26M 4.97M 5.24M 5.57M 3.13M 15.67M
Liabilities 8.26M 4.97M 5.24M 5.57M 3.13M 15.67M
Stockholders' Equity Attributable to Parent 39.35M 71.48M 91.02M 117.96M 138.14M 27.17M
Common Stock, Shares, Outstanding 8.61M 8.61M 125.30M 126.62M 126.62M 47.55M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -29.76M -21.03M -20.94M -20.76M -16.47M -11.57M
Payments to Acquire Property, Plant, and Equipment 23.00K 19.00K 14.00K 27.00K 9.00K 9.00K
Net Cash Provided by (Used in) Investing Activities -23.00K -19.00K -14.00K -4.73M -9.00K -9.00K
Payments for Repurchase of Common Stock 0 1.48M 0
Net Cash Provided by (Used in) Financing Activities 0 3.67M -1.48M 0 113.30M 38.55M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (ATOS CIK 0001488039), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

GM

GENERAL MOTORS COMPANY

PRSO

PERASO INC.

AMIX

AUTONOMIX MEDICAL, INC.